SoviHep (Sofosbuvir) is approved in india in 2015 march...

About Hepatitis

“Hepatitis” means inflammation of the liver...

Read More
About Zydus

Zydus Cadila is a fully integrated, global healthcare...

Read More
About ZRC

The Zydus Research Centre is the dedicated...

Read More
About Patients

SoviHep is Sofosbuvir which is a drug used as part...

Read More

FAQs

What is hepatitis C?
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which is found in the blood of persons who have this disease. HCV is spread by contact with the blood of an infected person.. read more
Can HCV be spread within a household?
Yes, but this does not occur very often. If HCV is spread within a household, it is most likely due to direct exposure to the blood of an infected household member.. read more
Why do most persons remain infected?
Persons infected with HCV mount an antibody response to parts of the virus, but changes in the virus during infection result in changes that are not recognized by preexisting antibodies. This appears to be how the virus establishes and maintains long-lasting infection.. read more

About Zydus Cadila

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.

The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group. From a turnover of Rs. 250 crores in 1995, the group posted revenues of Rs. 6300 crores in FY13.

Today, Zydus Cadila holds a commanding position in the domestic pharma industry sweepstakes. Globally, the group has a strong presence in the regulated markets of the US, Europe (France & Spain), Japan and the high profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide. It aims to be a leading global healthcare provider with a robust product pipeline; opening up new pathways through innovation and quality excellence, achieve sales of Rs.10000 crore by 2015 and be a research-based company by 2020.. read more